- Home
- UTHR
as 12-20-2024 3:43pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 16.2B | IPO Year: | 1999 |
| Target Price: | $370.86 | AVG Volume (30 days): | 286.9K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 22.72 | EPS Growth: | 25.10 |
| 52 Week Low/High: | $208.62 - $417.82 | Next Earning Date: | 02-19-2025 |
| Revenue: | $2,756,200,000 | Revenue Growth: | 25.04% |
| Revenue Growth (this year): | 26.32% | Revenue Growth (next year): | 10.37% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 16 '24 | Sell | $368.16 | 9,439 | $3,492,572.64 | 7,400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 9 '24 | Sell | $367.27 | 9,822 | $3,610,755.58 | 7,400 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Dec 5 '24 | Sell | $374.37 | 7,700 | $2,882,649.00 | 36,710 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Dec 2 '24 | Sell | $371.31 | 10,000 | $3,705,074.31 | 7,400 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 25 '24 | Sell | $372.61 | 10,000 | $3,727,546.89 | 7,400 | |
| MAHON PAUL A | UTHR | EVP & GENERAL COUNSEL | Nov 21 '24 | Sell | $367.36 | 7,700 | $2,828,672.00 | 36,710 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 18 '24 | Sell | $359.43 | 10,000 | $3,592,071.27 | 7,400 | |
| Olian Judy D. | UTHR | Director | Nov 11 '24 | Sell | $412.48 | 1,750 | $721,840.00 | 5,655 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 11 '24 | Sell | $407.67 | 15,000 | $6,109,840.99 | 7,400 | |
| Mesa Nilda | UTHR | Director | Nov 8 '24 | Sell | $412.28 | 224 | $92,350.27 | 5,783 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Argus Research
a day ago
Daily – Vickers Top Buyers & Sellers for 12/20/2024
MT Newswires
4 days ago
United Therapeutics Insider Sold Shares Worth $3,701,377, According to a Recent SEC Filing
Business Wire
4 days ago
United Therapeutics Announces Successful World’s First UKidney Transplant
MT Newswires
11 days ago
United Therapeutics Insider Sold Shares Worth $3,676,877, According to a Recent SEC Filing
Zacks
12 days ago
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Zacks
15 days ago
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Zacks
22 days ago
Why Is United Therapeutics (UTHR) Up 1.1% Since Last Earnings Report?
Zacks
22 days ago
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.